KLRG1 Depletion Is a Novel Therapeutic Strategy for Patients with Mature T and NK/T-Cell Lymphomas

Bimarzhan Assatova(Whitehead Institute for Biomedical Research), Salvia Jain(Broad Institute), Jessica Beth Ziemba(Beth Israel Deaconess Medical Center), Elizabeth A. Morgan(Brigham and Women's Hospital), Foster Powers(University of Minnesota), David M. Weinstock(Broad Institute), Jeffrey A. Barnes(Harvard University), Abner Louissaint(Massachusetts General Hospital), Andrew Crabbe(Harvard University), Jaehyuk Choi(Northwestern University), Gail Newton(Massachusetts General Hospital), Matthew J. Cotton(Beth Israel Deaconess Medical Center), Thomas P. Loughran(University of Virginia Cancer Center), Tayla B. Heavican‐Foral(Dana-Farber Cancer Institute), Brandy Pinckney(Beth Israel Deaconess Medical Center), Jessica Duffy(Massachusetts General Hospital), Garrett Haskett(Beth Israel Deaconess Medical Center), David J. Feith(University of Virginia), P. Connor Johnson(Harvard University), Eric D. Jacobsen(Dana-Farber Cancer Institute), Christopher Trevisani(SUNY Upstate Medical University), Steven A. Greenberg(Brigham and Women's Hospital), Robert Willim(Beth Israel Deaconess Medical Center), Lei Yang(The University of Texas MD Anderson Cancer Center), Nora Scanlan(Massachusetts General Hospital), Won-Seog Kim(Samsung Medical Center), Ian Brain(Brigham and Women's Hospital)
Blood
November 15, 2022
Cited by 1


Related Papers